{"filing":{"accession_number":"0001493152-26-031328","cik":"0001962011","ticker":"KAPA","company_name":"Kairos Pharma, LTD.","form":"8-K","filing_date":"2026-06-30","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1962011/000149315226031328/form8-k.htm"},"events":[{"id":15145,"run_id":13513,"accession_number":"0001493152-26-031328","anchor_item_number":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses Item 5.07 results from Kairos Pharma's June 29, 2026 annual meeting of stockholders, including voting outcomes on five proposals: election of four directors, ratification of auditors (Weinberg \u0026 Company, P.A.), approval of a reverse stock split amendment (1:3 to 1:250 ratio at Board discretion), advisory approval of executive compensation, and approval of amendments to the 2023 Equity Incentive Plan (5M additional shares plus 5% evergreen provision). These results are material to investors as they reflect shareholder decisions on governance, capital structure, and equity incentives.","company_name":"Kairos Pharma, LTD.","ticker":"KAPA","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":12804,"accession_number":"0001493152-26-031328","item_number":null,"item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Item 5.07 results from Kairos Pharma's June 29, 2026 annual meeting of stockholders, including voting outcomes on five proposals: election of four directors, ratification of auditors (Weinberg \u0026 Company, P.A.), approval of a reverse stock split amendment (1:3 to 1:250 ratio at Board discretion), advisory approval of executive compensation, and approval of amendments to the 2023 Equity Incentive Plan (5M additional shares plus 5% evergreen provision). These results are material to investors as they reflect shareholder decisions on governance, capital structure, and equity incentives.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:32:44.649572+00:00","company_name":"Kairos Pharma, LTD.","ticker":"KAPA","filing_date":"2026-06-30"}]}